Skip to content

US · TMDX · MEDICAL - DEVICES

TransMedics Group, Inc. (TMDX) intrinsic value and stock valuation

$85.25as of 2026-11-21 · Mkt cap 2.9B

Data updated · price as of 2026-11-21

UndervaluedIC value is 20–50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

TransMedics Group, Inc. DCF and intrinsic value

InvestorsCraft values TMDX with the Chepakovich two-stage DCF model — currently rated undervalued. How the model works · Run your own DCF prefilled from TMDX’s statements →

TransMedics Group, Inc. Graham Number

Graham Number: $41.87d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Devices Andover, MA 01810 transmedics.com

How the business is doing

Fiscal 2016–2025, USD

Revenue
$605.5M+88.2% 5y CAGRd
20162025
Net income
$190.3M
20162025
Free cash flow
$133.6M
20162025
Total equity
$473.1M+35.4% 5y CAGRd
20162025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2016–2025, USD
20252024202320222021
Revenue$605.5M$441.5M$241.6M$93.5M$30.3M
Operating income$108.6M$37.5M-$-28.73M-$-31.44M-$-39.43M
Net income$190.3M$35.5M-$-25.03M-$-36.23M-$-44.22M
EPSd$4.69M$1.01M-$-769.68K-$-1.23M-$-1.6M
Operating cash flow$192.8M$48.8M-$-13.03M-$-45.82M-$-28.86M
Capital expenditure-$-59.25M-$-129.74M-$-179.06M-$-11.91M-$-3.52M
Free cash flow$133.6M-$-80.94M-$-192.09M-$-57.72M-$-32.38M
Total assets$1.07B$804.1M$706.1M$277.2M$134.9M
Total debt$469.7M$518.3M$516M$67.6M$43.8M
Net debt-$-18.68M$181.6M$121.1M-$-133.63M$18.2M
Total equity$473.1M$228.6M$137.2M$187.4M$67.9M
Cash and short-term investments$488.4M$336.7M$394.8M$201.2M$92.5M
Income statement
20252024202320222021
Revenue$605.5M$441.5M$241.6M$93.5M$30.3M
Cost of revenue$242.7M$179.5M$87.5M$28.2M$9.1M
Gross profit$362.8M$262.1M$154.1M$65.3M$21.2M
Research and development expenses$69.1M$56M$63.3M$26.8M$22.3M
Selling, general and administrative expenses$185.2M$168.6M$119.6M$69.9M$38.3M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$254.2M$224.6M$182.8M$96.7M$60.6M
Cost and expenses$496.9M$404M$270.4M$124.9M$69.7M
Interest income$0.00$0.00$12.5M$900K$0.00
Interest expense$13.8M$14.4M$10.8M$3.73M$3.87M
Depreciation and amortization$27.2M$19.8M$8.18M$3.48M$1.82M
Ebitda$148.5M$70M-$-7.7M-$-28.96M-$-38.49M
Operating income$108.6M$37.5M-$-28.73M-$-31.44M-$-39.43M
Total other income/expenses, net-$-1.06M-$-1.72M$2.06M-$-4.73M-$-4.75M
Income before tax$107.5M$35.8M-$-26.67M-$-36.16M-$-44.18M
Income tax expense-$-82.77M$320K-$-1.64M$70K$40K
Net income$190.3M$35.5M-$-25.03M-$-36.23M-$-44.22M
Weighted average shares outstanding$34M$33.2M$32.5M$29.6M$27.6M
Weighted average diluted shares outstanding$40.5M$35.2M$32.5M$29.6M$27.6M
Balance sheet
20252024202320222021
Cash and short-term investments$488.4M$336.7M$394.8M$201.2M$92.5M
Net receivables$84.3M$97.7M$63.6M$27.6M$5.93M
Inventory$48.9M$46.6M$44.2M$20.6M$14.9M
Total current assets$637.8M$497.2M$510.7M$252.3M$118.7M
Property, plant and equipment, net$332.8M$292.5M$180.5M$24.4M$15.7M
Goodwill and intangible assets$13.5M$13.7M$14.3M$0.00$0.00
Long-term investments$0.00$0.00$0.00$500K$500K
Total non-current assets$430.6M$306.9M$195.4M$24.9M$16.2M
Total assets$1.07B$804.1M$706.1M$277.2M$134.9M
Accounts payable$10.4M$10.3M$12.7M$3.34M$6.65M
Short-term debt$13.3M$2.73M$2.04M$1.44M$0.00
Deferred revenue$2.9M$1.74M$1.96M$240K$250K
Total current liabilities$89.3M$59.9M$54.9M$23.7M$23.2M
Long-term debt$456.4M$515.6M$513.9M$66.1M$43.8M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$506M$515.6M$513.9M$66.1M$43.8M
Capital lease obligations$0.00$6.25M$9.74M$8.86M$8.6M
Total liabilities$595.3M$575.5M$568.9M$89.8M$67M
Common stock$750.9M$697.2M$641.1M$666.3M$510.5M
Retained earnings-$-277.95M-$-468.24M-$-503.7M-$-478.68M-$-442.45M
Accumulated other comprehensive income (loss)$120K-$-360K-$-200K-$-230K-$-190K
Total equity$473.1M$228.6M$137.2M$187.4M$67.9M
Total investments$0.00$0.00$0.00$500K$67.4M
Total debt$469.7M$518.3M$516M$67.6M$43.8M
Net debt-$-18.68M$181.6M$121.1M-$-133.63M$18.2M
Cash flow statement
20252024202320222021
Net income$190.3M$35.5M-$-25.03M-$-36.23M-$-44.22M
Depreciation and amortization$27.2M$19.8M$8.18M$3.48M$1.82M
Stock-based compensation$36.9M$33.2M$19.8M$10.3M$6.88M
Change in working capital$17.3M-$-45M-$-44.35M-$-26.76M$3M
Accounts receivable$14M-$-34.31M-$-33.82M-$-21.68M$840K
Inventory-$-7.72M-$-8.35M-$-28.09M-$-8.02M-$-4.89M
Accounts payable-$-20K-$-1.4M$6.96M-$-3.27M$5.09M
Net cash provided by operating activities$192.8M$48.8M-$-13.03M-$-45.82M-$-28.86M
Investments in property, plant and equipment-$-59.25M$0.00-$-151.85M-$-11.91M-$-3.52M
Acquisitions, net$0.00$440K-$-14.89M$110K$0.00
Net cash used for investing activities-$-59.25M-$-129.3M-$-193.95M$54.5M$29.3M
Common stock issued$0.00$22.9M$7.11M$139.9M$1.39M
Common stock repurchased-$-140K$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$16.9M$22.9M$400.4M$167.9M$1.39M
Net change in cash$151.7M-$-58.16M$193.6M$175.6M$1M
Cash at end of period$488.9M$337.2M$395.3M$201.7M$26.1M
Operating cash flow$192.8M$48.8M-$-13.03M-$-45.82M-$-28.86M
Capital expenditure-$-59.25M-$-129.74M-$-179.06M-$-11.91M-$-3.52M
Free cash flow$133.6M-$-80.94M-$-192.09M-$-57.72M-$-32.38M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About TransMedics Group, Inc.

        TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.

        CEO
        Waleed H. Hassanein
        Employees
        898
        Beta
        1.88

        Explore

        Frequently asked questions

        What is the intrinsic value of TransMedics Group, Inc. (TMDX)?

        TransMedics Group, Inc. (TMDX) is currently undervalued based on the InvestorsCraft IC model — IC value is 20–50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is TMDX undervalued?

        TMDX trades at a price of $85.25 (Nov 21, 2026): undervalued — IC value is 20–50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.